The Precision Peptide Company Nears Commercial Launch of Needle-Free BPC-157 Patch as Final Testing Advances

First wearable peptide patch designed to expand BPC-157 beyond injectables and establish a multi-product transdermal peptide platform under Amino Innovations Vancouver, British Columbia--(Newsfile Corp. - May 7, 2026) - The Precision Peptide Company (CSE: BPC) (OTCQB: PNGAF) (the "Company" or "BPC"), a publicly traded wellness company focused on advanced peptide formulations and delivery systems, today provides an update on the development of its needle-free BPC-157 transdermal patch - a product designed to give consumers a frictionless route into the peptide category for the first time. The BPC-157 patch is currently in active testing, with results anticipated in the near term.